Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 1000 US Route 202, Raritan, NJ 08869, USA.
J Antimicrob Chemother. 2011 Oct;66(10):2298-307. doi: 10.1093/jac/dkr290. Epub 2011 Jul 20.
Antibiotic resistance is problematic in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii, and is often associated with serious infections. Carbapenems are often one of the few remaining therapeutic options, so it is important to monitor carbapenem activity against these pathogens and to identify resistance mechanisms.
Carbapenem susceptibilities were determined for 14 359 Enterobacteriaceae, 3614 P. aeruginosa and 994 A. baumannii from the USA (2007-09). Klebsiella pneumoniae with doripenem MICs ≥2 mg/L (n = 88), and P. aeruginosa (n = 452), A. baumannii (n = 349) and other enterics (n = 13) with doripenem MICs ≥4 mg/L were screened for carbapenem resistance mechanisms.
Doripenem/meropenem and imipenem susceptibilities for Enterobacteriaceae were >99% and 89%, respectively. Doripenem susceptibility (2007-09) for P. aeruginosa was 87.4%-84.1%; comparable to meropenem and higher than imipenem. For A. baumannii, doripenem susceptibility (2007-09) was 63%-58.2%; lower than imipenem and meropenem. Resistant K. pneumoniae had KPC and lacked porins OmpK35/OmpK36. In 2009, 3.4% of all K. pneumoniae possessed KPC. Five other enterics and one P. aeruginosa possessed KPC. Resistance mechanisms in P. aeruginosa were loss of porin OprD (90%), efflux (55%) and elevated AmpC activity (25%). Acquired carbapenemases OXA-23/-24 were present in 48% of resistant A. baumannii. VIM metallo-β-lactamases were present in three P. aeruginosa and one A. baumannii isolates.
Doripenem and meropenem were more active than imipenem against Enterobacteriaceae and P. aeruginosa from the USA. Carbapenem resistance mechanisms included serine carbapenemases, elevated AmpC activity, efflux and porin deficiencies occurring mostly in P. aeruginosa. Metallo-β-lactamases were found in <0.1% of isolates.
肠杆菌科、铜绿假单胞菌和鲍曼不动杆菌对抗生素的耐药性是一个问题,而且常常与严重感染有关。碳青霉烯类通常是为数不多的几种仍有治疗选择的抗生素之一,因此监测这些病原体对碳青霉烯类的活性并确定耐药机制非常重要。
对来自美国的 14359 株肠杆菌科、3614 株铜绿假单胞菌和 994 株鲍曼不动杆菌(2007-09 年)进行了碳青霉烯类药物敏感性检测。对美罗培南和亚胺培南药敏试验中介或耐药的肺炎克雷伯菌(Klebsiella pneumoniae)(n=88),美罗培南和亚胺培南药敏试验中介或耐药的铜绿假单胞菌(n=452)、鲍曼不动杆菌(n=349)和其他肠杆菌(n=13)进行了碳青霉烯类耐药机制的筛选。
肠杆菌科对多利培南/美罗培南和亚胺培南的药敏率分别>99%和 89%。2007-09 年铜绿假单胞菌对多利培南的药敏率为 87.4%-84.1%;与美罗培南相当,高于亚胺培南。2007-09 年鲍曼不动杆菌对多利培南的药敏率为 63%-58.2%;低于亚胺培南和美罗培南。耐药肺炎克雷伯菌产 KPC 且缺乏孔蛋白 OmpK35/OmpK36。2009 年,3.4%的肺炎克雷伯菌携带 KPC。其他 5 株肠杆菌和 1 株铜绿假单胞菌携带 KPC。铜绿假单胞菌的耐药机制为孔蛋白 OprD 缺失(90%)、外排(55%)和 AmpC 活性升高(25%)。48%的耐药鲍曼不动杆菌产 OXA-23/-24 型碳青霉烯酶。3 株铜绿假单胞菌和 1 株鲍曼不动杆菌携带 VIM 金属β-内酰胺酶。
多利培南和美罗培南对来自美国的肠杆菌科和铜绿假单胞菌的活性优于亚胺培南。碳青霉烯类耐药机制包括丝氨酸碳青霉烯酶、AmpC 活性升高、外排和孔蛋白缺失,这些主要发生在铜绿假单胞菌中。金属β-内酰胺酶在<0.1%的分离株中发现。